511 related articles for article (PubMed ID: 26214357)
21. Nanotechnology for in vivo targeted siRNA delivery.
Dahlman JE; Kauffman KJ; Langer R; Anderson DG
Adv Genet; 2014; 88():37-69. PubMed ID: 25409603
[TBL] [Abstract][Full Text] [Related]
22. Physicochemical characterization techniques for lipid based delivery systems for siRNA.
Kapoor M; Burgess DJ; Patil SD
Int J Pharm; 2012 May; 427(1):35-57. PubMed ID: 21979250
[TBL] [Abstract][Full Text] [Related]
23. Threatening cancer with nanoparticle aided combination oncotherapy.
Rawal S; Patel MM
J Control Release; 2019 May; 301():76-109. PubMed ID: 30890445
[TBL] [Abstract][Full Text] [Related]
24. Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery.
Xiong XB; Uludağ H; Lavasanifar A
Biomaterials; 2009 Jan; 30(2):242-53. PubMed ID: 18838158
[TBL] [Abstract][Full Text] [Related]
25. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS
Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572
[TBL] [Abstract][Full Text] [Related]
26. Polyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA.
Elzeny H; Zhang F; Ali EN; Fathi HA; Zhang S; Li R; El-Mokhtar MA; Hamad MA; Wooley KL; Elsabahy M
Drug Des Devel Ther; 2017; 11():483-496. PubMed ID: 28260861
[TBL] [Abstract][Full Text] [Related]
27. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
[TBL] [Abstract][Full Text] [Related]
28. Efficient nanocarriers of siRNA therapeutics for cancer treatment.
Subhan MA; Torchilin VP
Transl Res; 2019 Dec; 214():62-91. PubMed ID: 31369717
[TBL] [Abstract][Full Text] [Related]
29. Effective delivery of siRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers.
Boyer C; Teo J; Phillips P; Erlich RB; Sagnella S; Sharbeen G; Dwarte T; Duong HT; Goldstein D; Davis TP; Kavallaris M; McCarroll J
Mol Pharm; 2013 Jun; 10(6):2435-44. PubMed ID: 23611705
[TBL] [Abstract][Full Text] [Related]
30. Biomaterials in siRNA Delivery: A Comprehensive Review.
Ho W; Zhang XQ; Xu X
Adv Healthc Mater; 2016 Nov; 5(21):2715-2731. PubMed ID: 27700013
[TBL] [Abstract][Full Text] [Related]
31. Lipid-based Nanocarriers for siRNA Delivery: Challenges, Strategies and the Lessons Learned from the DODAX: MO Liposomal System.
Oliveira ACN; Fernandes J; Gonçalves A; Gomes AC; Oliveira MECDR
Curr Drug Targets; 2019; 20(1):29-50. PubMed ID: 29968536
[TBL] [Abstract][Full Text] [Related]
32. Co-delivery of doxorubicin and siRNA with reduction and pH dually sensitive nanocarrier for synergistic cancer therapy.
Chen W; Yuan Y; Cheng D; Chen J; Wang L; Shuai X
Small; 2014 Jul; 10(13):2678-87. PubMed ID: 24668891
[TBL] [Abstract][Full Text] [Related]
33. Attacking the genome: emerging siRNA nanocarriers from concept to clinic.
Alabi C; Vegas A; Anderson D
Curr Opin Pharmacol; 2012 Aug; 12(4):427-33. PubMed ID: 22726555
[TBL] [Abstract][Full Text] [Related]
34. Single-step assembly of cationic lipid-polymer hybrid nanoparticles for systemic delivery of siRNA.
Yang XZ; Dou S; Wang YC; Long HY; Xiong MH; Mao CQ; Yao YD; Wang J
ACS Nano; 2012 Jun; 6(6):4955-65. PubMed ID: 22646867
[TBL] [Abstract][Full Text] [Related]
35. Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer.
Chitkara D; Singh S; Mittal A
Ther Deliv; 2016; 7(4):245-55. PubMed ID: 27010986
[TBL] [Abstract][Full Text] [Related]
36. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
37. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
[TBL] [Abstract][Full Text] [Related]
38. Combinational drug delivery using nanocarriers for breast cancer treatments: A review.
Olov N; Bagheri-Khoulenjani S; Mirzadeh H
J Biomed Mater Res A; 2018 Aug; 106(8):2272-2283. PubMed ID: 29577607
[TBL] [Abstract][Full Text] [Related]
39. A non-covalent peptide-based strategy for siRNA delivery.
Crombez L; Charnet A; Morris MC; Aldrian-Herrada G; Heitz F; Divita G
Biochem Soc Trans; 2007 Feb; 35(Pt 1):44-6. PubMed ID: 17233597
[TBL] [Abstract][Full Text] [Related]
40. In vivo synergistic antitumor effect and safety of siRNA and lonidamine dual-loaded hierarchical targeted nanoparticles.
Zhang BF; Xing L; Qiao JB; Cui PF; Wang FZ; Zhang JL; Xu CX; Jiang HL
Int J Pharm; 2016 Jun; 506(1-2):207-13. PubMed ID: 27113867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
